A Study of OPD5 Followed by Autologous Stem Cell Transplant for Patients With Relapsed Refractory Multiple Myeloma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Sergio Giralt, MD
Memorial Sloan Kettering Cancer Centre, New York City, United States
Principal InvestigatorKOL profile →
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University Hospital Brno, Clinic of Internal Medicine - Hematology and Oncology
Brno, Czechia
- University Hospital Ostrava, Clinic of Hematooncology
Ostrava, Czechia
- Charles University and General Hospital in Prague, 1st Department of Medicine - Department of Hematology, First Faculty of Medicine
Prague, Czechia
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 27 May 2021
- Primary completion
- 31 Mar 2024
- Completion
- 31 Dec 2025
- Last update posted
- 26 Nov 2021
- Registered enrollment
- 0
- Registry id
- NCT04918511
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.